FDA Enforcement To Be More "Swift, Aggressive" As Centers Share Techniques
FDA's ramped up enforcement efforts will include a much more collaborative approach between the agency's centers, staffers told the Food and Drug Law Institute meeting on enforcement in Washington Oct. 13
You may also be interested in...
The hyponatremia drug is a selective vasopressin V2-receptor antagonist, like Astellas’ Vaprisol and Otsuka’s Samsca.
FDA enforcement initiative eliminates requirement for all warning letters to be reviewed by Office of Chief Counsel.
FDA's aggressive enforcement of its advertising standards, and the agency's new enforcement allies, mean that industry may now have more to fear from a citation letter